AI Article Synopsis
- Scientists have found that counting certain T cells, called ICOS-positive T cells, can help predict how well a cancer treatment works.
- This research looks at data and methods for checking these T cells in patients who are receiving a specific cancer therapy involving anti-CTLA-4 antibodies.
- By monitoring these cells, doctors might be able to tell sooner if the treatment is effective.
Article Abstract
Compelling experimental evidences point to monitoring of the absolute number of circulating ICOS-positive T cells as an early predictive marker of clinical activity of anti-CTLA-4 antibodies in cancer patients. Here, we report available data focusing on this issue and operative procedures to detect ICOS expression on circulating peripheral blood mononuclear cells during CTLA-4 blockade therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-4939-3338-9_13 | DOI Listing |
Publication Analysis
Top Keywords
icos expression
8
expression immunologic
4
immunologic marker
4
marker immune
4
immune activating
4
activating monoclonal
4
monoclonal antibodies
4
antibodies compelling
4
compelling experimental
4
experimental evidences
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!